Listed

Monte Rosa Therapeutics, Inc.

GLUENasdaqCIK 1826457HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$9.0mRevenue, Q2 FY2026, three months to 2026-06-30$9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$9.0mRevenue, Q2 FY2026, three months to 2026-06-30$9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Report this figure−61.3% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−547.8%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$49.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Revenue: $9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Report this figure−480.8 pts on a year earlier
  • Net margin−483.9%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$43.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Revenue: $9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Report this figure−430.9 pts on a year earlier
  • Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
  • Free cash flow−$48.8mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$44.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-336711. Derived: 6-month figure less the 3-month figure.Capital expenditure: $4.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-336711. Derived: 6-month figure less the 3-month figure.Report this figure−34.1% on a year earlier

Last eight quarters

Full statements
Revenue$9.0mOperating margin −547.8%
Free cash flow−$48.8m, Q2 FY2026
Monte Rosa Therapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m9.2Revenue, Q3 FY2024, three months to 2024-09-30$9.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-268045.Report this figure60.6Revenue, Q4 FY2024, three months to 2024-12-31$60.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Report this figure84.9Revenue, Q1 FY2025, three months to 2025-03-31$84.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-210358.Report this figure23.2Revenue, Q2 FY2025, three months to 2025-06-30$23.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Report this figure12.8Revenue, Q3 FY2025, three months to 2025-09-30$12.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-268045.Report this figure2.8Revenue, Q4 FY2025, three months to 2025-12-31$2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Report this figure4.2Revenue, Q1 FY2026, three months to 2026-03-31$4.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-210358.Report this figure9.0Revenue, Q2 FY2026, three months to 2026-06-30$9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(287.8%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$26.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-268045.Revenue: $9.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-268045.Report this figure21.4%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $13.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Revenue: $60.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Report this figure51.9%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $44.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-210358.Revenue: $84.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-210358.Report this figure(67.1%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$15.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Revenue: $23.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Report this figure(258.3%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$33.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-268045.Revenue: $12.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-268045.Report this figure(1787.7%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$49.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Revenue: $2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Report this figure(1188.5%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$50.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-210358.Revenue: $4.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-210358.Report this figure(547.8%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$49.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Revenue: $9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Report this figure
Net margin%(258.9%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$23.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-268045.Revenue: $9.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-268045.Report this figure22.2%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $13.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Revenue: $60.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Report this figure55.2%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $46.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Revenue: $84.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-210358.Report this figure(53.0%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$12.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Revenue: $23.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Report this figure(212.1%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$27.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-268045.Revenue: $12.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-268045.Report this figure(1658.0%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$46.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336711. Derived: 12-month figure less the 9-month figure.Revenue: $2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Report this figure(1057.1%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$44.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Revenue: $4.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-210358.Report this figure(483.9%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$43.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Revenue: $9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m(21.4)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$21.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-268045. Derived: 9-month figure less the 6-month figure.Capital expenditure: $399.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-268045. Derived: 9-month figure less the 6-month figure.Report this figure129Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $128.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Capital expenditure: $183.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Report this figure(47.1)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$45.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-210358.Capital expenditure: $1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-210358.Report this figure(36.4)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$34.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-336711. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-336711. Derived: 6-month figure less the 3-month figure.Report this figure99.8Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $100.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-268045. Derived: 9-month figure less the 6-month figure.Capital expenditure: $651.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-268045. Derived: 9-month figure less the 6-month figure.Report this figure(43.8)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$43.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Capital expenditure: $767.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-17, accession 0001193125-26-109360. Derived: 12-month figure less the 9-month figure.Report this figure(39.2)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$37.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-210358.Capital expenditure: $1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-210358.Report this figure(48.8)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$44.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-336711. Derived: 6-month figure less the 3-month figure.Capital expenditure: $4.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-336711. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$123.7mOperating margin −43.8%
Diluted EPS−$2.96, FY2021
Free cash flow−$27.5m, FY2025
Monte Rosa Therapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$mnot reported (Revenue not reported)not reported (Revenue not reported)0.0Revenue, FY2023, twelve months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-20, accession 0000950170-25-042344.Report this figure75.6Revenue, FY2024, twelve months to 2024-12-31$75.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-17, accession 0001193125-26-109360.Report this figure124Revenue, FY2025, twelve months to 2025-12-31$123.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-17, accession 0001193125-26-109360.Report this figure
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue of zero not reported)(107.3%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$81.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-17, accession 0001193125-26-109360.Revenue: $75.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-17, accession 0001193125-26-109360.Report this figure(43.8%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$54.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-17, accession 0001193125-26-109360.Revenue: $123.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-17, accession 0001193125-26-109360.Report this figure
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue of zero not reported)(96.1%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$72.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-17, accession 0001193125-26-109360.Revenue: $75.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-17, accession 0001193125-26-109360.Report this figure(31.2%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$38.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336711.Revenue: $123.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-17, accession 0001193125-26-109360.Report this figure
Diluted EPS$ per share(2.96)Diluted EPS, FY2021, twelve months to 2021-12-31−$2.96 per share. XBRL concept us-gaap:EarningsPerShareBasicAndDiluted. 10-K filed 2022-03-29, accession 0000950170-22-004927.Report this figurenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m(69.1)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$59.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-16, accession 0000950170-23-008440.Capital expenditure: $9.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-16, accession 0000950170-23-008440.Report this figure(105)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$92.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-14, accession 0000950170-24-031150.Capital expenditure: $12.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-14, accession 0000950170-24-031150.Report this figure(62.8)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$43.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-20, accession 0000950170-25-042344.Capital expenditure: $19.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-20, accession 0000950170-25-042344.Report this figure38.0Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $42.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-17, accession 0001193125-26-109360.Capital expenditure: $4.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-17, accession 0001193125-26-109360.Report this figure(27.5)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$22.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-17, accession 0001193125-26-109360.Capital expenditure: $4.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-17, accession 0001193125-26-109360.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Monte Rosa Therapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
NEA Management Company, LLC2026-06-30$186.2m7,692,298Unchanged
BlackRock, Inc.2026-06-30$165.6m6,843,087Added+1,205,403
TCG Crossover Management, LLC2026-06-30$111.9m4,622,151Unchanged
Vestal Point Capital, LP2026-06-30$111.3m4,600,000Added+996,535
BVF INC/IL2026-06-30$108.0m4,460,886Unchanged
BAKER BROS. ADVISORS LP2026-06-30$105.2m4,345,736Unchanged
STATE STREET CORP2026-06-30$90.3m3,731,416Added+377,436
MONTANOVA CAPITAL, LLC2026-06-30$85.9m3,549,539Reduced−677,270
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$82.6m3,412,927Added+312,682
Versant Venture Management, LLC2026-06-30$77.0m3,180,780Unchanged

Recent filings

All 398 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Monte Rosa Therapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-0111:38 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-409833
2026-09-0811:02 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-384360
2026-08-0611:09 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-336711
2026-08-0611:04 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-336681
2026-07-0621:51 ETSCHEDULE 13D/AOwnership report, active investor, amended0001072613-26-000558
2026-06-1120:01 ET8-K5.07 Shareholder vote results0001193125-26-267465
2026-05-0711:30 ET10-QQuarterly reportPeriod 2026-03-310001193125-26-210358
2026-05-0711:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-210298
2026-04-2920:01 ETDEF 14AProxy statementPeriod 2026-04-290001193125-26-191439
2026-03-1920:05 ETSCHEDULE 13D/AOwnership report, active investor, amended0001072613-26-000294

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 17, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1826457
Tickers
GLUE
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
<br>Emerging growth company
Former names
Monte Rosa Therapeutics, Inc. (to 2026-10-06)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.